Warfarin dose prediction in children using pharmacometric bridging: comparison with published pharmacogenetic dosing algorithms
2013 (English)In: European Journal of Clinical Pharmacology, ISSN 0031-6970, E-ISSN 1432-1041, Vol. 69, no 6, 1275-1283 p.Article in journal (Refereed) Published
Numerous studies have investigated causes of warfarin dose variability in adults whereas studies in children are limited both in numbers and size. Mechanism-based population modelling provides an opportunity to condense and propagate prior knowledge from one population to another. The main objectives with this study were to evaluate the predictive performance of a theoretically bridged adult warfarin model in children, and to compare accuracy in dose prediction relative to published warfarin algorithms for children.
An adult population PK/PD-model for warfarin, with CYP2C9 and VKORC1 genotype, age and target INR as dose predictors, was bridged to children using allometric scaling methods. Its predictive properties were evaluated in an external dataset of children 0-18 years old, including comparison of dose prediction accuracy with three pharmacogenetics-based algorithms for children.
Overall, the bridged model predicted INR response well in 64 warfarin treated Swedish children (median age 4.3 years), but with a tendency to over predict INR in children ≤ 2 years old. The bridged model predicted 20 of 49 children (41%) within ± 20% of actual maintenance dose (median age 7.2 years). In comparison the published dosing algorithms predicted 33-41% of the children within ± 20% of actual dose. Dose optimization with the bridged model based on up to three individual INR observations increased the proportion within ± 20% of actual dose to 70%.
A mechanism-based population model developed on adult data provides a promising first step towards more individualized warfarin therapy in children.
Place, publisher, year, edition, pages
2013. Vol. 69, no 6, 1275-1283 p.
PK/PD model, Population analysis, Warfarin, Dosing, Children, Genotype
Research subject Clinical Pharmacology
IdentifiersURN: urn:nbn:se:uu:diva-197596DOI: 10.1007/s00228-012-1466-4ISI: 000318865600008OAI: oai:DiVA.org:uu-197596DiVA: diva2:613631
FunderSwedish Heart Lung Foundation
Correction in: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY Volume: 69, Issue: 9, Pages: 1737-1737, DOI: 10.1007/s00228-013-1565-x2013-04-022013-03-292016-02-22Bibliographically approved